{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:13:45Z","timestamp":1778260425655,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Johns Hopkins Project Restore"},{"name":"Bart Mclean Fund"},{"name":"Transverse Myelitis Association"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jns.2017.01.023","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T19:02:36Z","timestamp":1483815756000},"page":"303-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders"],"prefix":"10.1016","volume":"373","author":[{"given":"Paula","family":"Barreras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen A.","family":"Mealy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-5335","authenticated-orcid":false,"given":"Carlos A.","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.01.023_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.091463","article-title":"Tumor necrosis factor and anti-tumor necrosis factor therapies","volume":"85","author":"Keystone","year":"2010","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.jns.2017.01.023_bb0010","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism \u2013 by what mechanisms could tumor necrosis factor a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2017.01.023_bb0015","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2017.01.023_bb0020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2710.2006.00779.x","article-title":"Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report","volume":"31","author":"Cay","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jns.2017.01.023_bb0025","series-title":"Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (Marketed as Remicade, Enbrel, Humira, and Cimzia)","author":"U. S. Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.jns.2017.01.023_bb0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1742-2094-5-45","article-title":"TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease","volume":"5","author":"McCoy","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2017.01.023_bb0035","first-page":"S134","article-title":"Demyelination and inhibition of tumor necrosis factor (TNF)","volume":"22","author":"Magnano","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jns.2017.01.023_bb0040","first-page":"1202","article-title":"Entercept induced multiple sclerosis and transverse myelitis","volume":"33","author":"Saieg","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jns.2017.01.023_bb0045","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jaad.2013.08.047","article-title":"Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis","volume":"70","author":"Escalas","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jns.2017.01.023_bb0050","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jns.2017.01.023_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy-associated neurological disorders","volume":"7","author":"Bosch","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2017.01.023_bb0060","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.2011.04484.x","article-title":"Role of tumor necrosis factor (TNF)-\u03b1 and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis","volume":"16","author":"Caminero","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jns.2017.01.023_bb0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410230405","article-title":"Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro","volume":"23","author":"Selmaj","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2017.01.023_bb0070","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1568-9972(03)00048-X","article-title":"The biology of TNF blockade","volume":"2","author":"Suryaprasad","year":"2003","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2017.01.023_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0923-2494(97)87239-2","article-title":"The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire","volume":"148","author":"Cope","year":"1997","journal-title":"Res. Immunol."},{"key":"10.1016\/j.jns.2017.01.023_bb0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory","year":"2012","journal-title":"Nature"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17300242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17300242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:48:06Z","timestamp":1758383286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17300242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":16,"alternative-id":["S0022510X17300242"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.01.023","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}